Construct: ORF ccsbBroad304_00047
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF007322.1_s304c1, BRDN0000408592
- Derived from:
- ccsbBroadEn_00047
- DNA Barcode:
- None
- Epitope Tag:
- V5 (not translated due to prior stop codon)
- Notes:
- Early stop codon detected
Originally Annotated References:
- Gene:
- AKT2 (208)
Vector Information:
- Vector Backbone:
- pLX_304
- Pol II Cassette 1:
- PGK-BlastR
- Pol II Cassette 2:
- CMV-ccsbBroad304_00047
- Selection Marker:
- BlastR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
| Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
|---|---|---|---|---|---|---|---|---|
| 1 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | NM_001626.6 | 96.8% | 58.7% | (many diffs) |
| 2 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526614.1 | 96.8% | 58.7% | (many diffs) |
| 3 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526615.1 | 96.8% | 58.7% | (many diffs) |
| 4 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526616.1 | 96.8% | 58.7% | (many diffs) |
| 5 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526618.1 | 96.8% | 58.7% | (many diffs) |
| 6 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526619.1 | 96.8% | 58.7% | (many diffs) |
| 7 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526620.1 | 96.8% | 58.7% | (many diffs) |
| 8 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_017026470.2 | 96.8% | 58.7% | (many diffs) |
| 9 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_024451416.1 | 96.8% | 58.7% | (many diffs) |
| 10 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | NM_001330511.1 | 88.8% | 62.3% | (many diffs) |
| 11 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_024451417.1 | 88.8% | 62.3% | (many diffs) |
| 12 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | NM_001243027.3 | 84% | 45.9% | (many diffs) |
| 13 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | NM_001243028.3 | 84% | 45.9% | (many diffs) |
| 14 | human | 208 | AKT2 | AKT serine/threonine kinase 2 | XM_011526622.2 | 80.1% | 70.5% | (many diffs) |
| 15 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | NM_001110208.2 | 87.7% | 57.5% | (many diffs) |
| 16 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | NM_001331108.1 | 87.7% | 57.5% | (many diffs) |
| 17 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | NM_001331109.1 | 87.7% | 57.5% | (many diffs) |
| 18 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | NM_007434.4 | 87.7% | 57.5% | (many diffs) |
| 19 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | XM_006539477.1 | 87.7% | 57.5% | (many diffs) |
| 20 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | XM_006539480.1 | 87.7% | 57.5% | (many diffs) |
| 21 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | XM_006539481.3 | 87.7% | 57.5% | (many diffs) |
| 22 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | XM_006539482.1 | 79.7% | 48.6% | (many diffs) |
| 23 | mouse | 11652 | Akt2 | thymoma viral proto-oncogene 2 | XM_006539483.1 | 79.7% | 48.6% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 69
- ORF end:
- 1047
- ORF length:
- 978
- Sequence:
-
1 ggtctatata agcagagctc tctggctaac tgtcgggatc aacaagtttg tacaaaaaag 61 ttggcaccat gaatgaggtg tctgtcatca aagaaggctg gctccacaag cgtggtgaat 121 acatcaagac ctggaggcca cggtacttcc tgctgaagag cgacggctcc ttcattgggt 181 acaaggagag gcccgaggcc cctgatcaga ctctaccccc cttaaacaac ttctccgtag 241 cagaatgcca gctgatgaag accgagaggc cgcgacccaa cacctttgtc atacgctgcc 301 tgcagtggac cacagtcatc gagaggacct tccacgtgga ttctccagac gagagggagg 361 agtggatgcg ggccatccag atggtcgcca acagcctcaa gcagcgggcc ccaggcgagg 421 accccatgga ctacaagtgt ggctccccca gtgactcctc cacgactgag gagatggaag 481 tggcggtcag caaggcacgg gctaaagtga ccatgaatga cttcgactat ctcaaactcc 541 ttggcaaggg aacctttggc aaagtcatcc tggtgcggga gaaggccact ggccgctact 601 acgccatgaa gatcctgcgg aaggaagtca tcattgccaa ggatgaagtc gctcacacag 661 tcaccgagag ccgggtcctc cagaacacca ggcacccgtt cctcactgcg ctgaagtatg 721 ccttccagac ccacgaccgc ctgtgctttg tgatggagta tgccaacggg ggtgagctgt 781 tcttccacct gtcccgggag cgtgtcttca cagaggagcg ggcccggttt tatggtgcag 841 AGATCTTCTC GGCTCTCGAG TACTTGCACT CCCCGGGACG TGGTATACCG CGACATCAAG 901 CTGGAAAACC TCATCCTGGA CAAAGACGGG CACGTCAAGA TCACTTGCCT TGGGTCTCTG 961 CAAAGAGGGC ATCAGTGACG GGGCCCCCCA TGAAAACCTT CTTTGGGCCC CCCGAGTTCC 1021 TGGCGCCCGA AGTTGCGGGA GGACAATGAC TTATGGCCGG GCCGTGGACT GGTGGGGGCT 1081 GGGTGTGGTC ATGTCAGAGC AGATGTGCGG CCGCCTGCCC TTCTACAACC AGGGCCGCGA 1141 GCGCCTCTCC GAGCTCATCC TCATGGAAGG AGATCCGCTT CCTGGCGCAC GCTCAGCCCG 1201 AGGCCAAGTC CCTGCTTGCT GGGCTGCTTA AAGAACGACC CCAAGCAGAG GCTTGGTGGG 1261 GGGCCCAGCG ATGCCAAGGA GGTCATGGAG CACAGGTTCT TCCTCAGCAT CAACTGGCAG 1321 GACGTGGTCC AGAAGAAGCT CCTGCCCCCC TTCAAACCTC AGGTCACGTC CGAGGTCGAC 1381 ACAAGGTACT TCGATGATGA ATTTACCGCC CAGTCCATCA CAATCAAACC CCCTGACCGC 1441 TATGACAGCC TGGGCTTTCT GGAGCTGGAC CAGCGGACCC ACTTCCCCCA GTTCTCCCTC 1501 TCGGCTCTCA TCCCCGAGTA CCCACTTTCT TGGACAAAAG GGTTGGGTAG CCCGTCCCTA 1561 CCCTCTCCTC GGTCTCGATT CTACGTAGTA ATGAGCTAGC GCTACCCGGG GGCGCGTTAA 1621 GTCGACAATC AACCTCTGGA TTACAAAATT TGTGAAAGAT TGACTGGTAT TCTTAACTAT 1681 GTTGCTCCTT TTACGCTATG TGGATACGCT GCTTTAATGC CTTGTATCAT GCTATCCTCC